{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-316063","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.259655+00:00","generated_at":"2026-05-16T13:36:07.899090+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants","bullets":["Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.","Maximum leverage ratio set at 4.25x for Q4 2025 and thereafter; can increase 0.5x for acquisitions over $250M.","Covenants suspended if Teva achieves Investment Grade Status (Baa3/BBB- from two agencies); reinstated on loss or default.","Consent fee of 0.08% of total commitments paid to lenders approving the amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-316063","json":"https://secwatch.observer/filing/0001193125-25-316063.json","markdown":"https://secwatch.observer/filing/0001193125-25-316063.md","text":"https://secwatch.observer/filing/0001193125-25-316063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000119312525316063/0001193125-25-316063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000119312525316063/d46386d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:36:07.899090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}